Cancer BiologyMolecular Cancer TherapeuticsPeer-reviewed
CerS2 is a druggable target in triple-negative breast cancer
Hissah Alatawi, Nair Hariprasad Haritha, Lingbao Ai…·Satya Narayan
This paper identifies DH20931 as a first-in-class agonist of CerS2 that induces ER stress and apoptosis in TNBC cells, showing preclinical efficacy.
1 citation